CI=conﬁdence interval; DFS=disease-free survival; HR=hazard ratio; NC=not calculated; OS=overall survival; PFS=progression-free survival.
*In patients with Stage II to IIIA resected EGFRm NSCLC (primary endpoint), adjuvant TAGRISSO reduced the risk of recurrence or death by 83% vs placebo (HR=0.17 [99.06% CI: 0.11, 0.26]; P<0.001). Median DFS was not reached in the TAGRISSO arm (95% CI: 38.8, NC) vs 19.6 months in the placebo arm (95% CI: 16.6, 24.5).1
†Median DFS: not reached in the adjuvant TAGRISSO arm.1
‡PFS was the primary endpoint. OS was a prespeciﬁed secondary endpoint; statistically signiﬁcant HR for OS was demonstrated (HR=0.799; 95.05% CI: 0.641, 0.997; P=0.0462).2,3
references: 1. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383(18):1711-1723. 2. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2021. 3. Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.